[1]覃磊 综述 肖庆澳 张晓磷**审校.钇-90微球选择性内放射治疗神经内分泌肿瘤肝转移的研究进展[J].中国微创外科杂志,2024,01(9):633-637.
点击复制

钇-90微球选择性内放射治疗神经内分泌肿瘤肝转移的研究进展()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2024年9期
页码:
633-637
栏目:
文献综述
出版日期:
2024-09-25

文章信息/Info

作者:
覃磊 综述 肖庆澳 张晓磷**审校
(宜昌市中心人民医院介入放射科三峡大学第一临床医学院，宜昌443003)
文献标志码:
A

参考文献/References:

[1]Horn SR,Stoltzfus KC,Lehrer EJ,et al.Epidemiology of liver metastases.Cancer Epidemiol,2020,67:101760.
[2]Riihimki M,Hemminki A,Sundquist K,et al.The epidemiology of metastases in neuroendocrine tumors.Int J Cancer,2016,139(12):2679-2686.
[3]Frilling A,Modlin IM,Kidd M,et al.Recommendations for management of patients with neuroendocrine liver metastases.Lancet Oncol,2014,15(1):e8-e21.
[4]Mayo SC,de Jong MC,Pulitano C,et al.Surgical management of hepatic neuroendocrine tumor metastasis:results from an international multiinstitutional analysis.Ann Surg Oncol,2010,17(12):3129-3136.
[5]Braat AJAT,Kappadath SC,Ahmadzadehfar H,et al.Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases:international multicenter study on efficacy and toxicity.Cardiovasc Intervent Radiol,2019,42(3): 413-425.
[6]Inchingolo R,Cortese F,Pisani AR,et al.Selective internal radiation therapy segmentectomy:a new minimally invasive curative option for primary liver malignancies?World J Gastroenterol,2024,30(18):2379-2386.
[7]牛惠敏,王志恒,高石鑫,等.钇90放射性微球在肝脏恶性肿瘤中的应用及进展.肝癌电子杂志,2021,8(4):36-40.
[8]Adcock CS,Florez E,Zand KA,et al.Assessment of treatment response following yttrium90 transarterial radioembolization of liver malignancies.Cureus,2018,10(6):e2895.
[9]Ebbers SC,van Roekel C,Braat MNGJA,et al.Doseresponse relationship after yttrium90radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.Eur J Nucl Med Mol Imaging,2022,49(5):1700-1710.
[10]Murthy R,Nunez R,Szklaruk J,et al.Yttrium90 microsphere therapy for hepatic malignancy:devices,indications,technical considerations,and potential complications.Radiographics,2005,25 Suppl 1:S41-S55.
[11]Cremonesi M,Chiesa C,Strigari L,et al.Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective.Front Oncol,2014,4:210.
[12]Peltek OO,Muslimov AR,Zyuzin MV,et al.Current outlook on radionuclide delivery systems: from design consideration to translation into clinics.J Nanobiotechnology,2019,17(1):90.
[13]中国临床肿瘤学会核医学专家委员会,北京市核医学质量控制和改进中心.钇-90(90Y)微球选择性内放射治疗原发性和转移性肝癌的中国专家共识.中华肝脏病杂志,2021,29(7):648-658.
[14]中国医师协会介入医师分会临床诊疗指南专委会,中国研究型医院学会肝胆胰外科专业委员会.钇-90微球选择性内放射治疗肝脏恶性肿瘤规范化操作专家共识(2024版).中华医学杂志,2024,104(7):486-498.
[15]吴文铭,陈洁,白春梅,等.中国胰腺神经内分泌肿瘤诊疗指南(2020).中华消化外科杂志,2021,20(6):579-599.
[16]郑致远,颜志平.钇90放射性微球治疗肝脏恶性肿瘤的应用进展.复旦学报(医学版),2020,47(4):622-627.
[17]中国临床肿瘤学会神经内分泌肿瘤专家委员会.中国胃肠胰神经内分泌肿瘤专家共识(2022年版).中华肿瘤杂志,2022,44(12):1305-1329.
[18]Clift AK,Frilling A.Liverdirected therapies for neuroendocrine neoplasms.Curr Oncol Rep,2021,23(4):44.
[19]Weber M,Lam M,Chiesa C,et al.EANM procedure guideline for the treatment of liver cancer and liver metastases with intraarterial radioactive compounds.Eur J Nucl Med Mol Imaging,2022,49(5):1682-1699.
[20]Wong TY,Zhang KS,Gandhi RT,et al.Longterm outcomes following 90Y Radioembolization of neuroendocrine liver metastases:evaluation of the radiationemitting SIRspheres in nonresectable liver tumor (RESiN) registry.BMC Cancer,2022,22(1):224.
[21]Schaarschmidt BM,Wildgruber M,Kloeckner R,et al.90Y radioembolization in the treatment of neuroendocrine neoplasms:results of an international multicenter retrospective study.J Nucl Med,2022,63(5):679-685.
[22]Do Minh D,Chapiro J,Gorodetski B,et al.Intraarterial therapy of neuroendocrine tumour liver metastases:comparing conventional TACE,drugeluting beads TACE and yttrium90 radioembolisation as treatment options using a propensity score analysis model.Eur Radiol,2017,27(12):4995-5005.
[23]Ingenerf M,Grawe F,Winkelmann M,et al.Neuroendocrine liver metastases treated using transarterial radioembolization:identification of prognostic parameters at 68GaDOTATATE PET/CT.Diagn Interv Imaging,2024,105(1):15-25.
[24]Barat M,Cottereau AS,Kedra A,et al.The role of interventional radiology for the treatment of hepatic metastases from neuroendocrine tumor:an updated review.J Clin Med,2020,9(7):2302.
[25]Currie BM,Hoteit MA,BenJosef E,et al.Radioembolizationinduced chronic hepatotoxicity:a singlecenter cohort analysis.J Vasc Interv Radiol,2019,30(12):1915-1923.
[26]Tomozawa Y,Jahangiri Y,Pathak P,et al.Longterm toxicity after transarterial radioembolization with yttrium90 using resin microspheres for neuroendocrine tumor liver metastases.J Vasc Interv Radiol,2018,29(6):858-865.
[27]Su YK,Mackey RV,Riaz A,et al.Longterm hepatotoxicity of yttrium90 radioembolization as treatment of metastatic neuroendocrine tumor to the liver.J Vasc Interv Radiol,2017,28(11):1520-1526.
[28]Currie BM,Nadolski G,Mondschein J,et al.Chronic hepatotoxicity in patients with metastatic neuroendocrine tumor:transarterial chemoembolization versus transarterial radioembolization.J Vasc Interv Radiol,2020,31(10):1627-1635.
[29]Soulen MC,van Houten D,Teitelbaum UR,et al.Safety and feasibility of integrating yttrium90 radioembolization with capecitabinetemozolomide for grade 2 liverdominant metastatic neuroendocrine tumors.Pancreas,2018,47(8):980-984.
[30]Soulen MC,Teitelbaum UR,Mick R,et al.Integrated capecitabinetemozolomide with radioembolization for liverdominant G2 NETs:longterm outcomes of a singleinstitution retrospective study.Cardiovasc Intervent Radiol,2024,47(1):60-68.
[31]Kim HS,Shaib WL,Zhang C,et al.Phase 1b study of pasireotide,everolimus,and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.Cancer,2018,124(9):1992-2000.
[32]Braat AJAT,Ahmadzadehfar H,Kappadath SC,et al.Radioembolization with 90Y resin microspheres of neuroendocrine liver metastases after initial peptide receptor radionuclide therapy.Cardiovasc Intervent Radiol,2020,43(2):246-253.
[33]Egger ME,Armstrong E,Martin RC 2nd,et al.Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multiinstitutional analysis.J Am Coll Surg,2020,230(4):363-370.
[34]Ngo L,Elnahla A,Attia AS,et al.Chemoembolization versus radioembolization for neuroendocrine liver metastases:a metaanalysis comparing clinical outcomes.Ann Surg Oncol,2021,28(4):1950-1958.
[35]Eshmuminov D,Studer DJ,Lopez Lopez V,et al.Controversy over liver transplantation or resection for neuroendocrine liver metastasis: tumor biology cuts the deal.Ann Surg,2023,277(5):e1063-e1071.
[36]Singla S,LeVea CM,Pokuri VK,et al.Ki67 score as a potential predictor in the selection of liverdirected therapies for metastatic neuroendocrine tumors:a single institutional experience.J Gastrointest Oncol,2016,7(3):441-448.
[37]Cholapranee A,van Houten D,Deitrick G,et al.Risk of liver abscess formation in patients with prior biliary intervention following yttrium90 radioembolization.Cardiovasc Intervent Radiol,2015,38(2):397-400.
[38]Whitney R,Vàlek V,Fages JF,et al.Transarterial chemoembolization and selective internal radiation for the treatment of patients with

备注/Memo

备注/Memo:
基金项目：宜昌市指导性科技项目计划(B22-2-002)**通讯作者，Email：zhangxiaolin5800@163.com
更新日期/Last Update: 2024-12-17